Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 28;22(1):258.
doi: 10.1186/s12890-022-02046-3.

Real-life effectiveness of dupilumab in patients with mild to moderate bronchial asthma comorbid with CRSwNP

Shunsuke Minagawa  1   2 , Jun Araya  3 , Naoaki Watanabe  3   4 , Shota Fujimoto  3   4 , Junko Watanabe  3   4 , Hiromichi Hara  3 , Takanori Numata  3 , Kazuyoshi Kuwano  3 , Yoshinori Matsuwaki  4
Affiliations

Real-life effectiveness of dupilumab in patients with mild to moderate bronchial asthma comorbid with CRSwNP

Shunsuke Minagawa et al. BMC Pulm Med. .

Abstract

Background: Dupilumab, an anti-IL-4α receptor antibody, is a new treatment for severe or refractory asthma. However, real-world evidence on the efficacy of dupilumab in patients with mild to moderate bronchial asthma is lacking.

Methods: We retrospectively evaluated the effects of dupilumab in 62 patients who received dupilumab for eosinophilic sinusitis comorbid with asthma at a single centre in Japan. Type 2 inflammatory markers, ACT, respiratory function tests, and forced oscillation technique (FOT) were analysed before, three months after, and one year after dupilumab administration, mainly in patients with mild to moderate asthma.

Results: FEV1, %FEV1, %FVC, treatment steps for asthma and ACT improved significantly after three months of dupilumab treatment. FeNO was markedly decreased, whereas IgE and eosinophil counts showed no significant changes. Pre- and post-treatment respiratory resistance (Rrs) and respiratory reactance (Xrs) correlated significantly with FEV1. Improvement in %FEV1 was associated with higher FeNO and higher serum IgE before dupilumab treatment.

Conclusion: Dupilumab treatment for sinusitis may improve respiratory functions, asthma symptoms, and asthma treatment reduction, even if the associated bronchial asthma is not severe.

Keywords: Bronchial asthma; Chronic sinusitis; Dupilumab; Forced oscillation technique; Nasal polyps.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no financial or non-financial types of interest related to the submitted article.

Figures

Fig. 1
Fig. 1
Evaluation of clinical parameters in patients with mild to moderate asthma. Changes in Type 2 inflammatory markers (A),asthma control indicators (B),and sinusitis treatment Indicators (C) at 3 months and 1 year after dupilumab administration are shown in A. Pre and 3 month: n = 50, 1 year: n = 18. Each panel shown represents the mean ± SD. *p < 0.05,**p < 0.01 by student’s t test
Fig. 2
Fig. 2
Assessment of respiratory function and impedance in patients with mild to moderate asthma. Changes in respiratory function by spirometry (A) and changes in respiratory resistance by FOT (B) at 3 months and 1 year after dupilumab administration are shown. Pre and 3 month: n = 50, 1 year: n = 18. Each panel shown represents the mean ± SD. *p < 0.05, **p < 0.01 by student’s t test
Fig. 3
Fig. 3
Correlation between respiratory function test (FEV1) and respiratory impedance test. A Correlation between respiratory function test (FEV1) and respiratory impedance are shown. n = 50 in each panel. *p < 0.05,**p < 0.01 by the Pearson correlation coefficient. B The improvement rates (%) of FEV1 and R5 after three months of dupilumab treatment in patients with FEV1/FVC above and below the mean (80.8%) are shown. n = 50 in each panel. *p < 0.05, **p < 0.01 by unpaired t test
Fig. 4
Fig. 4
Comparison of the efficacy of dupilumab treatment according to disease severity. The improvement rate of FEV1, %FEV1, %FVC, ACT, treatment-step, and FeNO by asthma severity are shown. Mild-moderate; n = 50, Severe; n = 12. *p < 0.05, **p < 0.01 by unpaired t test
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Numata T, Miyagawa H, Nishioka S, Okuda K, Utsumi H, Hashimoto M, et al. Efficacy of benralizumab for patients with severe eosinophilic asthma: A retrospective, real-life study. BMC Pulm Med. 2020;20(1). - PMC - PubMed
    1. Numata T, Araya J, Miyagawa H, Okuda K, Fujita Y, Utsumi H, et al. Effectiveness of switching biologics for severe asthma patients in Japan: a single-center retrospective study. J Asthma Allergy. 2021;14:609–618. doi: 10.2147/JAA.S311975. - DOI - PMC - PubMed
    1. Harada N, Ito J, Takahashi K. Clinical effects and immune modulation of biologics in asthma. Respir Investig. 2021;59(4):389–396. doi: 10.1016/j.resinv.2021.03.003. - DOI - PubMed
    1. Napoletano F, Baron O, Vandenabeele P, Mollereau B, Fanto M. Intersections between regulated cell death and autophagy. Trends Cell Biol. 2018 doi: 10.1016/j.tcb.2018.12.007. - DOI - PubMed
    1. Dragonieri S, Carpagnano GE. Biological therapy for severe asthma. Asthma Res Pract. 2021;7(1). - PMC - PubMed